跳至主要内容
临床试验/NCT00642876
NCT00642876已完成不适用

Investigation of the PRESTIGE® Cervical Disc Device at a Single Level for Symptomatic Cervical Disc Disease

Medtronic Spinal and Biologics62 个研究点 分布在 1 个国家目标入组 541 人开始时间: 2002年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
541
试验地点
62
主要终点
The primary endpoint is overall success, which consists of NDI score, neuro status success, with/without FSU disc ht success, no serious AE classified as "implant/surgical procedure associated", and no secondary surgical procedure classified as failure

研究概览

简要总结

The purpose of this clinical investigation is to evaluate the safety and effectiveness of the ACD in the single level surgical treatment of patients with symptomatic cervical degenerative disc disease. The primary follow-up information obtained from this clinical investigation are used to support a PMA application for the ACD.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients participating in this study must meet all of the following inclusion criteria:
  • Cervical degenerative disc disease defined as:
  • intractable radiculopathy and/or myelopathy with at least one of the following items producing symptomatic nerve root and/or spinal cord compression which is documented by patient history (e.g., neck and/or arm pain], functional deficit, and/or neurological deficit, and radiographic studies (e.g., CT, MRI, x-rays, etc).
  • herniated disc;
  • osteophyte formation;
  • One cervical level requiring surgical treatment;
  • C3-C4 disc to C6-C7 disc level of involvement;
  • Unresponsive to non-operative treatment for approximately six weeks or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative management;
  • No previous surgical intervention at the involved level or any subsequent, planned/staged surgical procedure at the involved or adjacent level(s);
  • Is at least 18 years of age, inclusive, at the time of surgery;
  • Preoperative Neck Disability Index score > or = 30;
  • Has a preoperative neck pain score of > 20 based on the Preoperative Neck and Arm Pain Questionnaire.
  • If of child-bearing potential, patient is not pregnant at the time of surgery;
  • Is willing to comply with the study plan and sign the Patient Informed Consent Form.

排除标准

  • A patient meeting any of the following criteria is to be excluded from the study:
  • Has a cervical spinal condition other than symptomatic cervical disc disease requiring surgical treatment at the involved level;
  • Documented or diagnosed cervical instability defined by dynamic (flexion/extension) radiographs showing:
  • Sagittal plane translation > 3.5 mm or;
  • Sagittal plane angulation >
  • More than one cervical level requiring surgical treatment;
  • Has a fused level adjacent to the level to be treated;
  • Has severe pathology of the facet joints of the involved vertebral bodies;
  • Previous surgical intervention at the involved level;
  • Has been previously diagnosed with osteopenia or osteomalacia;
  • Has any of the following that may be associated with a diagnosis of osteoporosis (if Yes to any of the below risk factors, a DEXA Scan will be required to determine eligibility):
  • Postmenopausal Non-Black female over 60 years of age and weighs less than 140 pounds.
  • Postmenopausal female that has sustained a non-traumatic hip, spine, or wrist fracture.
  • Male over the age of
  • Male over the age of 60 that has sustained a non-traumatic hip or spine fracture.
  • If the level of BMD is a T score of -3.5 or a T score of -2.5 with vertebral crush fracture, then the patient is excluded from the study.
  • Has presence of spinal metastases;
  • Has overt or active bacterial infection, either local or systemic;
  • Has severe insulin dependent diabetes;
  • Has chronic or acute renal failure or prior history of renal disease;
  • Has fever (temperature > 101 F oral) at the time of surgery;
  • Has a documented allergy or intolerance to stainless steel, titanium, or a titanium alloy;
  • Is mentally incompetent. (If questionable, obtain psychiatric consult);
  • Is a prisoner;
  • Is pregnant;
  • Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug abuse;
  • Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal surgery (e.g., steroids or methotrexate), excluding routine perioperative anti-inflammatory drugs;
  • Has a history of an endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's Disease, renal osteodystrophy, Ehlers-Danlos Syndrome, or osteogenesis imperfecta);
  • Has a condition that requires postoperative medications that interfere with the stability of the implant or fusion, such as steroids. (This does not include low dose aspirin for prophylactic anticoagulation and routine perioperative anti-inflammatory drugs);
  • Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the16 weeks following Artificial Cervical Disc implantation.

结局指标

主要结局

The primary endpoint is overall success, which consists of NDI score, neuro status success, with/without FSU disc ht success, no serious AE classified as "implant/surgical procedure associated", and no secondary surgical procedure classified as failure

时间窗: 24 months

次要结局

  • The secondary outcomes are radiographic success, medical outcomes SF-36 patient survey (MCS & PCS) success, neck pain status, arm pain status, patient satisfaction, patient global perceived effect, gait assessment, foraminal compression test(24 months)

研究者

发起方
Medtronic Spinal and Biologics
申办方类型
Industry
责任方
Sponsor

研究点 (62)

Loading locations...

相似试验